CNTX
Context TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bullish interpretation centers on the June 2026 CTIM-76 interim data readout, with additional support from CT-202 moving toward first-patient dosing in Q3 2026 and cash runway into mid-2027. If the data are clean and the platform starts to look clinically differentiated, the stock could rerate sharply from a low base.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.2.
What can break
CT-202 first-patient dosing could slip beyond the Q3 2026 target, reinforcing execution concerns.
Momentum
99
Value
41
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.30 · Bull $5.63 · Bear $1.05
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.63
Why
Momentum99 · Δ7d +0.2
Value41 · Δ7d +0.1
Sentiment59 · Δ7d +10.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
34% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
59
33% active weight
Current posture
7d trendImproving
Δ7d
+10.4
Δ21d
-
Why this grade
Composite grade A. Momentum 99.1 / Value 41.1 / Sentiment 58.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$256.34M
Beta
1.91
Shares Out
91.88M
P/E (TTM) · Derived
-6.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.45
Rev YoY
-
EPS YoY
+53.1%
Gross Margin
-
Op Margin
-
Net Debt
-$94.43M
Current Ratio
13.10
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology